Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALLO-501A · 1 trial · 1 indication
Dose limiting toxicity is defined as protocol-defined ALLO-501A-related adverse events with onset within 28 days following infusion
DLT is defined as protocol-defined ALLO-647-related adverse events with onset within 33 days following 1st infusion
ORR defined as assessment of CR and PR using Lugano classification criteria 2014
| Arm | Type | Description |
|---|---|---|
| ALLO-501A, ALLO-647 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ALLO-501A | GENETIC | ALLO-501A is an allogeneic CAR T cell therapy targeting CD19 |
| ALLO-647 | BIOLOGICAL | ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen |
| Fludarabine | DRUG | Chemotherapy for lymphodepletion |
| Cyclophosphamide | DRUG | Chemotherapy for lymphodepletion |
Inclusion Criteria: For subjects with LBCL: * Histologically confirmed diagnosis of relapsed/refractory large B-cell lymphoma at last relapse per WHO 2017 * At least 1 measurable lesion at time of enrollment * Relapsed or refractory disease after at least 2 lines of chemotherapy * Absence of signi...
ALLO-501A is an investigational allogeneic CAR T cell therapy being studied for the treatment of relapsed or refractory large B cell lymphoma, relapsed or refractory chronic lymphocytic leukemia, and relapsed or refractory small lymphocytic lymphoma. It is currently in Phase 1 clinical development.
ALLO-501A targets CD19, a protein found on the surface of B cells. By targeting CD19, the therapy is designed to recognize and eliminate cancerous B cells in patients with certain types of lymphoma and leukemia.
ALLO-501A is being developed by Allogene Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol ALLO. The company is focused on developing allogeneic CAR T cell therapies for cancer.
ALLO-501A is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. The therapy has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
ALLO-501A is being studied in a Phase 1 clinical trial with the identifier NCT04416984, known as the ALPHA2 trial. This trial is evaluating the safety and efficacy of ALLO-501A in adults with relapsed or refractory large B cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. The trial is active but not recruiting participants.
ALLO-501A is a distinct product candidate from ALLO-501, though both are allogeneic CAR T cell therapies targeting CD19 developed by Allogene Therapeutics. ALLO-501A is being evaluated in the ALPHA2 trial for specific relapsed or refractory B cell malignancies.